Mundipharma announces European approval of REZZAYO® (rezafungin) for the treatment of Invasive Candidiasis in adults

Mundipharma today announced rezafungin (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults.


The approval by the European Commission (EC) follows the positive opinion of the Committee...

Related Keywords

Germany ,Canada ,United States ,America ,Yuri Martina ,Asia Pacific ,Oliver Cornely ,Antimicrob Chemother ,Product Service ,University Hospital Cologne ,Community Register ,European Union ,Data Review Committee ,European Commission ,Committee For Medicinal Products Human Use ,Cidara Therapeutics Inc ,Invasive Candidiasis ,Medicinal Products ,Human Use ,European Excellence Centre ,Medical Mycology ,Chief Development ,Medical Officer ,Orphan Drug Designation ,Latin America ,Cidara Therapeutics ,Patient Level Meta Analysis ,Multicenter Phase ,Rev Dis Primers ,Englj Med ,Database Syst Rev ,